The abnormal cells express the same target protein we successfully treat in myeloma.
In a quiet but consequential moment for rare disease medicine, three patients in the United Kingdom have become the first in Europe to receive CAR T-cell therapy for light chain amyloidosis — a condition that claims lives through organ failure and, until now, offered little recourse when standard treatment failed. The ALARIC trial, led by researchers at University College London Hospital, asks whether the immune system, once reprogrammed, might accomplish in a single intervention what months of chemotherapy cannot. It is a question that carries within it the broader human hope that medicine might one day meet suffering not with prolonged endurance, but with something closer to a cure.
- Light chain amyloidosis affects roughly five hundred people in Britain each year, and for those whose disease resists or relapses after chemotherapy, no licensed treatment exists — leaving patients facing organ failure with nowhere left to turn.
- Standard treatment demands six months of weekly chemotherapy followed by up to eighteen more months of maintenance, exacting a relentless toll of nausea, sleeplessness, and diminished quality of life even when it works.
- CAR T-cell therapy offers a fundamentally different logic: a patient's own immune cells are genetically reprogrammed to hunt and destroy the abnormal plasma cells producing amyloid proteins, potentially replacing months of infusions with a single, durable intervention.
- The ALARIC trial has already produced a striking early signal — one patient's faulty protein levels fell from around two hundred to nearly undetectable after his infusion, a result he described simply as saying it all.
- The trial aims to treat at least twelve patients over two years, with safety as its primary focus, while researchers watch closely for evidence that interrupting the disease at its source might also allow damaged organs a genuine chance to recover.
Three patients in the United Kingdom have become the first in Europe to receive CAR T-cell therapy for light chain amyloidosis, a rare blood disorder affecting roughly five hundred people annually in Britain and carrying no current cure. The treatment is being delivered through the ALARIC trial at University College London Hospital, led by researchers at UCL and UCLH, and represents a fundamental departure from how this disease has long been managed.
Light chain amyloidosis occurs when faulty immune cells produce misfolded proteins that accumulate in organs, potentially causing organ failure and death. The standard response — six months of weekly chemotherapy followed by up to eighteen months of maintenance — is often effective but relentless. Patients endure nausea, disrupted sleep, and a quality of life worn thin by prolonged treatment. For those whose disease resists or returns after chemotherapy, no licensed therapy exists.
CAR T-cell therapy works differently. A patient's own T cells are extracted and reprogrammed in the laboratory to recognize and destroy the abnormal plasma cells responsible for producing amyloid proteins, targeting a protein called BCMA already proven effective in the related blood cancer multiple myeloma. If successful in amyloidosis, it could offer a single treatment with lasting results — and give damaged organs a real chance to heal.
The trial's principal investigator, Dr. Lydia Lee, described the stakes plainly: for patients with relapsed or resistant disease, options are severely constrained and progression often means suffering and death. Professor Ashutosh Wechalekar, chief investigator, noted that while safety remains the primary focus of this phase one study, the scientific rationale is compelling — the same cellular target successfully treated in myeloma is present in amyloidosis.
Tim Wiberg, sixty-one, of Sheffield, was the third patient to receive the therapy. His illness began with a subtle sign — persistently frothy urine — that eventually led, after months of investigation and a kidney biopsy, to his diagnosis. Six months of chemotherapy reduced his disease but only partially. "It was tough. Not unbearable, but relentless," he said. When offered a place in the trial, he accepted, sensing his options were narrowing and that this represented something genuinely new.
He received his CAR T cells on March 2nd and recovered at home within two weeks. The measure of what followed was stark: before any treatment, his lambda light chains — the faulty proteins that define the disease — numbered around two hundred. After the infusion, they became almost undetectable. "That really says it all," he said.
Three patients in the United Kingdom have become the first in Europe to receive CAR T-cell therapy for light chain amyloidosis, a rare blood disorder that strikes roughly five hundred people annually across Britain and currently has no cure. The treatment, delivered through the ALARIC trial at University College London Hospital and led by researchers at UCL and UCLH, represents a fundamental departure from the standard approach to this disease—one that has left many patients with limited options when conventional medicine fails them.
Light chain amyloidosis develops when faulty immune cells manufacture misfolded proteins that accumulate in tissues and organs, potentially triggering organ failure and death. The established treatment involves six months of weekly chemotherapy followed by maintenance therapy stretching up to eighteen months more. While often effective, this regimen exacts a heavy toll. Patients endure significant side effects, disrupted sleep, nausea that lingers, and a quality of life diminished by the relentless nature of prolonged treatment. For those whose disease resists chemotherapy or returns after initial response, the medical landscape becomes bleak. No licensed therapy exists for them.
CAR T-cell therapy operates on an entirely different principle. Doctors extract a patient's own T cells—immune cells central to fighting disease—and reprogram them in the laboratory to recognize and destroy the abnormal plasma cells responsible for producing amyloid proteins. The therapy targets BCMA, a protein present on these harmful cells. This approach has already transformed outcomes in multiple myeloma, a related blood cancer where abnormal plasma cells also express BCMA. If successful in amyloidosis, it could offer patients a single treatment with durable results, potentially allowing damaged organs a genuine chance to heal.
The ALARIC trial, developed within the UK Myeloma Research Alliance and supported by the National Institute for Health and Care Research Biomedical Research Centre, aims to treat at least twelve patients over the next two years at UCLH, with plans to expand to Leeds shortly. Dr. Lydia Lee, principal investigator and consultant haematologist at UCLH, emphasized the stakes: for patients with disease that has relapsed or resisted standard chemotherapy, options are severely constrained, and progression often means suffering and death. Professor Ashutosh Wechalekar, chief investigator and consultant hematologist at both UCLH and the Royal Free London NHS Trust, stressed that while this is a phase one study prioritizing safety, the scientific logic is compelling. The abnormal plasma cells in amyloidosis express the same target protein successfully treated in myeloma. Interrupting the disease at its source could not only control the condition but substantially improve how patients live.
Tim Wiberg, sixty-one, of Sheffield, became the third patient to receive CAR T cells through the trial. Nearly two years before his diagnosis, his urine turned persistently frothy—a sign that initially seemed minor but eventually led to the discovery of protein in his urine. After months of investigation and a kidney biopsy, amyloidosis was confirmed. He felt physically well, but the emotional weight of the diagnosis was substantial. "A diagnosis like this takes time to sink in," he said. "I'm not sure I've fully come to terms with it even now. It's a life-changing disease."
Wiberg endured six months of weekly chemotherapy combined with steroids. The treatment reduced his disease but only partially. "It was tough. Not unbearable, but relentless," he recalled. Sleep became impossible. The experience consumed his life for half a year. When offered a place in the CAR T trial, he hesitated, then accepted. Standard treatment had taken him only so far, and his options seemed to be narrowing. This trial offered something genuinely new—a different way forward, carrying risks but also hope.
He received his CAR T cells on March 2nd and recovered at home. The chemotherapy beforehand had been grueling, producing nausea that persisted for weeks. The immunotherapy itself proved straightforward, and his recovery was swift. Two weeks in hospital, with the most difficult part being nurses checking his vitals every few hours—though he praised their care without reservation. The measure of his response tells the story most clearly: before any treatment, his lambda light chains, the faulty proteins that define amyloidosis, numbered around two hundred. After the infusion, they became almost undetectable. "That really says it all," he said.
Citas Notables
For patients with relapsed or refractory AL amyloidosis, treatment options are extremely limited, and their disease is likely to progress causing suffering and even death.— Dr. Lydia Lee, principal investigator, UCLH
If we can interrupt the disease process at its source, we may be able not only to control the condition but also to improve patients' quality of life.— Professor Ashutosh Wechalekar, chief investigator
La Conversación del Hearth Otra perspectiva de la historia
Why does this trial matter now, when CAR T therapy has already worked in myeloma?
Because amyloidosis patients have been left behind. When chemotherapy doesn't work or stops working, there's literally nothing else. This is the first time anyone in Europe has tried to use this approach on them.
What makes you confident it will work here when it works in myeloma?
The abnormal cells in both diseases express the same target protein—BCMA. The science is the same. But amyloidosis is different enough that you can't just assume success. That's why this is phase one. Safety first.
Tim Wiberg's lambda light chains dropped from 200 to almost undetectable. Is that the kind of result that changes everything?
It's one patient, three total so far. But yes—that's the kind of response that makes researchers believe they're onto something real. One person's dramatic improvement doesn't prove the therapy works for everyone, but it justifies continuing.
What was the hardest part of his experience?
Not the immunotherapy itself—that was straightforward. It was the chemotherapy beforehand, combined with steroids. Six months of that destroyed his sleep, his energy, his sense of normalcy. That's what makes a one-time CAR T treatment so appealing.
Why does organ recovery matter so much in this disease?
Because amyloidosis damages organs—kidneys, heart, nerves. If you can stop the disease at its source by eliminating the cells producing the faulty proteins, the organs might actually heal instead of continuing to fail. That's not just about survival. It's about living well.
What happens if this trial fails?
Then amyloidosis patients go back to having almost no options. But if it works, even partially, it opens a door that's been closed. That's why people like Tim are willing to take the risk.